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Objective: Between 65% and 75% of patients with metastatic breast cancer will have decreased 5-year survival
and increased morbidity due to cancer relapse in bone. At this stage of disease treatment is palliative, but
tumor-targeted compounds could add to the beneﬁts of anti-resorptive agents, improving clinical outcome.
Inhibitor-of-apoptosis proteins (IAPs) are overexpressed in many tumors and second mitochondria-derived
activator of caspases (Smac) mimetics have been designed to antagonize IAPs. In this work we explored the use
of AT-406, a Smac mimetic, to target the tumor compartment of bone metastases.
Methods: Effect of AT-406 on cancer cells apoptosis, expression of IAPs and osteogenic potential was
addressed in vitro using the RANK-positive MDA-MB-231 breast cancer cell line. Effect of AT-406 on
osteoclastogenesis was determined by inducing the differentiation of the RAW 264.7 mouse monocytic cell
line. Osteoclastogenesis was measured by TRAP staining and TRACP 5b quantiﬁcation.
Results: AT-406 increased apoptosis in MDA-MB-231 breast cancer cells in vitro, and activation of RANK-
pathway improved this effect. RANKL stimuli induced a strong increase in c-IAP2. AT-406 increased osteoclast
differentiation and activity, by up-regulating the osteogenic transcription factor Nfatc1, but also increased the
apoptosis of mature osteoclasts in the absence of RANKL.
Conclusions: Our results indicate that despite the anti-tumoral effect of AT-406, its use in the context of bone
metastatic disease needs to be carefully monitored for the induction of increased bone resorption. We also
hypothesize that the combination of AT-406 with anti-RANKL directed therapies could have a beneﬁcial
effect, especially in RANK-positive tumors.
& 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Between 65% and 75% of patients with metastatic breast cancer
will have decreased 5-year survival and increased morbidity due
to cancer relapse in bone [1,2]. Bone metastases phenotype results
from an unbalanced bone remodeling, where in a “vicious cycle”
the tumor cells stimulate osteoclast activity, and have increased
proliferation due to growth factors released from bone matrix
upon bone resorption [3].
Currently available therapeutics for bone metastatic disease are
palliative and target mainly the bone component, with the use of
anti-resorptive agents that will decrease bone osteolysis and
associated morbidity. The tumor itself is only indirectly affected
by the decrease in growth factors, and tumor burden often
progresses. Therefore, the use of anti-tumoral agents is appealing
at this stage of disease.. This is an open access article und
ology Research Unit, Instituto
3-A-5, Av. Prof. Egas Moniz,
+351 217951780.Re-establishing the apoptotic program in tumor cells is a promising
strategy for cancer therapy. Inhibitor-of-apoptosis proteins (IAPs) are
inhibitors of caspases’ pathways that prevent cells from undergoing
apoptosis. IAPs are frequently overexpressed in cancer and contribute
to tumor cell survival, chemoresistance, disease progression and poor
prognosis. IAPs are also potent regulators of nuclear factor k-B (NF-kB)
and tumor-necrosis factor (TNF) receptor signaling pathways [4–6].
Cells have natural IAP antagonists, like Smac (second mitochon-
dria-derived activator of caspases)/DIABLO in mammals, that bind to
caspases preventing further IAPs binding [7,8]. Based on this, Smac
mimetics have been designed to antagonize IAPs and cause cancer
cells to undergo apoptosis [9–11]. Also, it has been shown that IAPs are
direct activators of tumor cell motility and metastatic genes indepen-
dently of their roles in cytoprotection, suggesting that IAP antagonists
could provide antimetastatic therapies for patients with cancer [12].
AT-406 (formerly SM-406) is a potent and orally bioavailable
Smac mimetic and an antagonist of IAPs [11]. This compound
binds to XIAP, cIAP1, and cIAP2 proteins, induces rapid degradation
of IAPs, and inhibits cancer cell growth in various human cancer
cell lines. AT-406 is currently in phase I clinical trial for the
treatment of human cancer (NCT01078649).er the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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compartment of bone metastases, using an in vitromodel of breast
cancer. Since cIAP1 and cIAP2 were originally identiﬁed through
their ability to interact directly with TNF-family [13], and MDA-
MB-231 breast cancer cells express the receptor activator of NF-κB
(RANK) [14–18] and are sensitive to RANK ligand (RANKL) that
induces the activation of RANK–TRAF-dependent pathways
[14–16,19,20], we also explored the activation of RANKL–RANK
pathway in these cells and its signiﬁcance on AT-406 effect. Given
that IAPs also play a role in osteoclastogenesis, the effect of IAP
antagonists on osteoclasts needs to be addressed if AT-406 is used
in the context of bone metastatic disease. Recently, it was
demonstrated that IAPs negatively regulate osteoclastogenesis by
inhibiting NFATc1 mRNA expression [21]. It was also shown that
IAP antagonists induce high turnover osteoporosis characterized
by enhanced osteoclast and osteoblast activities, in mice, and may
increase tumor growth and metastasis in the bone by stabilizing
NF-κB inducing kinase (NIK) and activating the alternative NF-κB
pathway in osteoclasts [22]. Therefore we also addressed the
effects of AT-406 in osteoclastogenesis and osteoclast activity
in vitro.2. Methods
2.1. Cell culture, cell proliferation and cell apoptosis assays
MCF 10A (CRL-10317, ATCC) normal mammary epithelial cells were
cultured in mammary epithelial cell basal medium (MEGM) contain-
ing 0.4% bovine pituitary extract (BPE), 0.1% human epidermal growth
factor (hEGF), 0.1% hydrocortisone, 0.1% gentamicin/amphotericin B
(GA-1000), 0.1% insulin, and 100 ng/ml cholera toxin. MDA-MB-231
(HTB-26, ATCC) breast cancer cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) containing 10% fetal bovine serum
(FBS) and 1% penicillin/streptomycin. Cells were maintained at 37 1C
with 5% CO2 in a humidiﬁed chamber.
MDA-MB-231 conditioned media (CM) were obtained as fol-
lows: 2104 cells were plated in 35 mm plates and allowed to
adhere for 12 h. Cells were treated with 1 mM AT-406, 2.5 mg/ml
RANKL, or AT-406+RANKL, for 24 h. Medium was collected, cen-
trifuged, and supernatant aliquots were stored at 80 1C.
For proliferation and apoptosis assays, MDA-MB-231 cells were
plated in 96-well plates (3103 cells/well, assayed in triplicate)
and incubated for 24 h, in the presence or absence of RANKL
(2.5 mg/ml). Cells were treated with different concentrations of
AT-406 (Ascenta; prepared in DMSO), or 0.1% DMSO for control,
and incubated for 24–48 h. Cell proliferation was analyzed by
alamarBlue assay (Invitrogen). Medium was replaced by 200 ml
fresh mediumwith 1:10 alamarBlue. After a 1 h incubation at 37 1C
with 5% CO2, ﬂuorescence was measured at 560/590 nm (excita-
tion/emission). Cell apoptosis was analyzed by measuring caspase-
3 and -7 activities using the Caspase-Glo 3/7 kit (Promega),
according to manufacturer’s instructions.
2.2. Osteoclastogenesis assays
RAW 264.7 mouse monocytic cells were cultured in DMEM
containing 10% heat inactivated FBS and 1% penicillin/streptomy-
cin. For differentiation cells were plated in 96-well plates (950
cells/well) in DMEM containing 10% heat inactivated FBS, 1%
penicillin/streptomycin, and 100 ng/ml RANKL (day 0). Medium
supplemented with AT-406 (10, 100, or 1000 nM) or 60% MDA-
MB-231 CM (obtained as described above) was changed at day 3.
Osteoclastogenesis was measured at day 5 by counting the number
of TRAP positive multinucleated cells/well after TRAP staining
(Sigma-Aldrich) and TRACP 5b quantiﬁcation by solid phaseimmunoﬁxed enzyme activity assay (IDS). For osteoclast survival
assay, differentiated osteoclasts were deprived from RANKL at day
5 and incubated with 100 nM AT-406 for 24 h under standard
conditions, before TRAP staining or TRACP 5b quantiﬁcation.
TRAP5b activity rate and TRAP+multinucleated cells are expressed
as a percentage of TRAP5b activity or TRAP+ multinucleated cells,
respectively, without RANKL deprivation at day 6.
2.3. RT-qPCR
2104 MDA-MB-231 cells were plated in 35 mm plates,
allowed to adhere for 12 h, and treated with 2.5 mg/ml RANKL for
60 min. 5104 RAW 264.7 mouse monocytic cells were plated in
35 mm plates, in differentiation medium as described above,
supplemented with 1 mM AT-406 for 72 h. Samples were collected
at different time points. Cells were rinsed in 1 PBS and RNeasy
mini spin column (Qiagen) were used for total RNA isolation
according to manufacturer’s instructions. DNase I (Promega) treat-
ment was performed to remove genomic DNA contamination and
RNA concentration and purity were assessed in a NanoDrop
spectrophotometer (Thermo Fisher Scientiﬁc). RNA (500 ng per
sample) was reverse transcribed using Superscript III First-Strand
Synthesis System for RT-PCR (Invitrogen) according to the manu-
facturer’s instructions with anchored oligo(dT) primer. cDNAs were
ampliﬁed by semi-quantitative real-time PCR (qPCR) using Power
SYBR Green PCR Master Mix (Applied Biosystems) and speciﬁc
primers for human RANK (PPH01102B), human cIAP1 (PPH07279B),
human cIAP2 (PPH00326B), human XIAP (PPH00323A), and human
GADPH (PPH00150E) (SABiosciences, Quiagen); and mouse Birc2,
mouse Birc3, mouse Nfatc1, and mouse β-actin [21], in a Rotor Gene
6000 (Corbett, Quiagen), for 40 cycles (95 1C for 15 s, 55 1C for 40 s,
and 72 1C for 30 s) after an initial incubation at 95 1C for 10 min.
Reactions were performed in triplicate. Target gene expression was
normalized against the housekeeping gene GAPDH (human) or β-
actin (mouse), using the mean value of the three replicates.
2.4. Western blot
For Western blot analysis of protein expression, cells were
cultured as described above. Neutralized RANKL was obtained by
incubating 2.5 mg/ml RANKL with an anti-RANKL antibody (2.5 mg/
ml; R&D), in culture medium, at 37 1C for 1 h. Cells were washed
once with PBS, lysed in 200 ml 2 SDS-loading buffer, and heated
to 95 1C for 10 min. Samples were loaded onto a 10% polyacryla-
mide gel and electrophoresis was performed using a Mini-
PROTEAN Tetra cell (BioRad). Proteins were transferred onto a
Protran BA85 nitrocellulose membrane (Whatman) using a Mini-
PROTEAN Tetra Cell transfer system (BioRad). Membranes were
blocked in PBST, 5% skim milk for 1 h, incubated overnight with
the primary antibody and for 2 h with the secondary antibody.
Antibody detection was performed using SuperSignal West Pico
Chemiluminescent HRP Substrate (Pierce) according to the man-
ufacturer’s directions and signal was visualized on radiographic
ﬁlm. Antibodies used include anti-cIAP1 (1E1-1-10, Enzo Life
sciences), anti-cIAP-2 (Clone 315304, R&D), and anti-NFATc1
(H-110, Santa Cruz); β-actin (Abcam) was used as control. Second-
ary antibodies conjugated to peroxidase were purchased from
Santa Cruz.
2.5. Statistical analysis
Data were analyzed with the use of Graphpad Prism v5.0
software. Samples were analyzed in triplicate for apoptosis,
osteoclastogenesis-related assays and RT-qPCR. Statistics were
analyzed by one-way ANOVA and Newman–Keuls or Dunnett’s
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and po0.05 was considered signiﬁcant.3. Results
3.1. Effect of AT-406 in MDA-MB-231 breast cancer cells
To assess the effect of the IAP antagonist AT-406 on the breast
cancer cell line MDA-MB-231 we measured apoptosis upon
treatment with different doses of AT-406 (Fig. 1a). AT-406
increased apoptosis as early as 24 h after treatment at the highest
concentration (po0.001). The effect was shown to be dose-
dependent at 48 h, when also the lower concentrations of AT-
406 have a signiﬁcant effect (po0.05 to po0.001). An increase in
apoptosis was observed in control cells treated with 0.1% DMSO,
48 h after treatment, due to cell proliferation and conﬂuence. As
expected, AT-406 induced the degradation of c-IAP1 and c-IAP2
(Fig. 1b).
It was previously reported by us and other authors that MDA-
MB-231 cells express RANK [14]; therefore we aimed to determine
if the activation of RANKL–RANK pathway could alter the effect of
AT-406 on apoptosis induction. RANKL treatment of RANK expres-
sing cells (Fig. 1c) increased the effect of AT-406 on apoptosis, by
24% at the highest concentration (po0.001) (Fig. 1d).
To explore the mechanism by which RANKL improved the
AT-406 effect we analyzed whether RANKL affected the expression
of IAPs. RANKL induced a strong increase in c-IAP2 mRNA (up to
4-fold, po0.001), a modest increase in c-IAP1 mRNA, and had no
effect on XIAP (Fig. 2a). Increase in c-IAPs was also shown at the
protein level (Fig. 2b).Fig. 1. Effect of AT-406 in survival of MDA-MB-231 breast cancer cells. Cell apoptosis was
MDA-MB-231 cells are sensitive to AT-406 in a dose-dependent manner (a). AT-406 (100
cIAP2 protein levels were normalized by densitometry to β-actin levels (b). RANK expr
expression of RANK (c). Cells were plated for 24 h, in the presence or absence of RANK
AT-406-induced apoptosis (d). n¼3, npo0.05, nnpo0.01, nnnpo0.005, using one-way A3.2. Effect of AT-406 in osteoclast differentiation in vitro
The possibility to use AT-406 for the therapy of bone metastatic
disease, and the fact that IAPs play a role in osteoclast differentia-
tion and survival, led us to address a possible effect of AT-406 in
osteoclastogenesis. RAW264.7 murine monocytic cells were cul-
tured in osteoclast differentiation medium in the presence of
AT-406 at different doses. AT-406 increased osteoclast differentia-
tion and activity in a dose-dependent manner (po0.05 to
po0.001) (Fig. 3a–c).
Next we aimed to determine the effect of AT-406 on the
survival of mature osteoclasts. To address this question, mature
osteoclasts were deprived from RANKL for 24 h, and treated with
100 nM AT-406. AT-406 signiﬁcantly decreased TRAP5b activity
and osteoclast number (po0.01 and po0.05, respectively) (Fig. 3d
and e).
To investigate the means by which AT-406 could increase
osteoclast differentiation, we analyzed its effect on the expression
of IAPs and the osteogenic transcription factor Nfatc1. Although
AT-406 had no effect on IAPs expression at the mRNA level, c-IAP2
was shown to be down-regulated during osteoclast differentiation
(Fig. 4a). However, AT-406 up-regulated Nfatc1 in the early stages
of differentiation (po0.05) (Fig. 4a). After 48 h, the levels of Nfatc1
were independent of AT-406. These results were conﬁrmed at the
protein level (Fig. 4b).
Since MDA-MB-231 breast cancer cells are able to stimulate
osteoclastogenesis, we wanted to analyze the effect of AT-406 on the
osteogenic potential of these cells. As expected, enrichment of
osteoclast differentiation medium with 60% conditioned medium
(CM) from MDA-MB-231 cells increased osteoclast differentia-
tion, and this effect was independent of RANKL stimuli to breast
cancer cells (po0.001) (Fig. 5). Our data show that the treatment ofanalyzed by measuring caspase-3 and -7 activities. 0.1% DMSO was used as control.
nM) induced the depletion of cIAP1 and 2 as analyzed by Western blot. cIAP1 and
ession was analyzed by RT-qPCR. MDA-MB-231 breast cancer cells show increased
L (2.5 mg/ml), prior to 48 h treatment with AT-406. RANKL stimulus increased the
NOVA with a Newman–Keuls multiple comparison test.
Fig. 2. Effect of RANKL in IAPs expression in MDA-MB-231 breast cancer cells. cIAP1, cIAP2 and XIAP expression were analyzed by RT-qPCR (a) and Western blot (b). Approx.
18 h post-treatment with RANKL (2.5 mg/ml), MDA-MB-231 breast cancer cells show a modest increase in cIAP1 expression, no effect on XIAP expression, but a highly
signiﬁcant increase in cIAP2 expression. RANKL neutralization with an anti-RANKL antibody abrogated this effect, as analyzed by Western blot. n¼3, npo0.05, nnpo0.01,
nnnpo0.005, using one-way ANOVA with a Dunnett multiple comparison test.
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the effect of the conditioned medium in osteoclastogenesis (Fig. 5).4. Discussion
In this work we explore the potential of AT-406 for the
treatment of breast cancer at advanced stages of disease, namely
in patients with bone metastases. Although at this stage of disease
therapy is only palliative, treatment should not only prevent and
decrease the secondary effects of disease, like increased bone
resorption, but also decrease tumor burden.
One of the hallmarks of cancer is the ability of cancer cells to
evade apoptosis. Inhibition of apoptosis not only enhances the
survival of cancer cells but also facilitates their escape from
chemotherapy [5]. Therefore, apoptosis regulatory mechanisms
are promising targets for anti-cancer therapy.
Inhibitors of apoptosis proteins (IAPs) are able to abrogate
death-inducing signals, by direct inhibition of caspases and mod-
ulation of NF-κB [23]. IAP antagonists are being tested in the
clinical setting for their ability to restore apoptosis in cancer cells.
In this work we conﬁrmed that MDA-MB-231 breast cancer
cells are sensitive to AT-406 by restoring apoptosis in this cell line
at nanomolar concentrations [11].
It was previously shown by us and other authors that RANK
(receptor activator of NF-κB) is expressed in vitro by several human
breast cancer cell lines, including MDA-MB-231 [15–18,24]. In
RANK-positive cells, RANKL (RANK ligand) induces the activation
of RANK-dependent pathway, increases migration and invasion,
and induces epithelia–mesenchymal transition, favoring an inva-
sive phenotype [14–16,19,20,25]. This fact is extremely relevant in
the context of bone metastases since the molecular triad RANK–RANKL–OPG (osteoprotegerin) controls bone remodeling. In bone
metastatic disease there is an unbalanced bone remodeling. Tumor
cells interact with the bone microenvironment and stimulate
osteoclastogenesis by releasing important factors like PTHrP
(parathyroid hormone-related protein). This leads to an increased
amount of growth factors released from bone matrix that further
promote tumor growth, in a “vicious cycle” [3,26]. In this work we
show that RANK-positive breast cancer cells show an up-
regulation of cIAP-2 when activated by RANKL, and are more
sensitive to AT-406, when using non-limiting concentrations of the
drug. In fact, it was previously reported that cIAP2 is one of the
most-upregulated genes in PC-3 prostate cancer cell line, which
expresses the highest levels of RANK, when stimulated with
RANKL [16]. Pharmacokinetics analysis of AT-406 on SCID mice
bearing MDA-MB-231 tumors has shown that AT-406 achieves a
maximum concentration in plasma between 1.5 μM and 9.9 μM,
and a maximum concentration in tumor tissue between 0.5 μM
and 18.2 μM, depending on the dose and administration route
(intravenous versus oral gavage) [11]. Therefore, the described
effects of AT-406 concentrations ranging from 100 nM to 1 μM
may be further increased in vivo.
It was formerly shown in an animal model of breast cancer
bone metastases that RANKL inhibition inhibits osteolysis induced
by MDA-MB-231 cells, but also enhances the ability of rhApo2L/
TRAIL to reduce skeletal tumor burden in vivo [27]. Therefore, it
may be important to address if AT-406 could be used in combina-
tion with an anti-RANKL therapy in the context of bone metastatic
disease.
It is known that IAPs also play a role in osteoclast differentia-
tion and survival. Osteoclast differentiation and function are
stimulated by activation of the alternative NF-κB pathway [28].
In monocytes, cIAP1 and 2, that have E3 ligase activity, are
Fig. 3. Effect of AT-406 in osteoclastogenesis. Osteoclasts were cultured in differentiation medium, with 0.1% DMSO or AT-406, for 5 days, and visualized after TRAP staining,
50 (a). Osteoclastogenesis was quantiﬁed at day 5 by measuring TRAP5b activity and counting the number of TRAP+multinucleated cells/well. Osteoclasts differentiated in
the presence of AT-406 show increased TRAP5b activity in a dose-dependent manner (b), and increased number of TRAP+ multinucleated cells (c). Mature osteoclasts were
deprived from RANKL and cultured with 0.1% DMSO or 100 nM AT-406 for 24 h. TRAP5b activity rate and TRAP+ multinucleated cells/well are expressed as a percentage of
TRAP5b activity or TRAP-positive cells, measured for mature osteoclasts without RANKL deprivation. AT-406 increased osteoclasts apoptosis in the absence of RANKL (d and
e). n¼3, npo0.05, nnpo0.01, nnnpo0.005, using one-way ANOVA with a Newman–Keuls multiple comparison test.
Fig. 4. Effect of AT-406 in IAPs and Nfatc1 expression in osteoclasts. cIAP1, cIAP2 and Nfatc1 expression were analyzed by RT-qPCR (a) and Nfatc1expression was also
analyzed by Western blot (b). 24 h post-treatment, RAW264.7 cells treated with AT-406 (1 mM) show a signiﬁcant increase in Nfatc1 expression at both mRNA and protein
level. n¼3, npo0.05, nnpo0.01, nnn po0.005, using one-way ANOVA with a Dunnett multiple comparison test.
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Fig. 5. Representative images of osteoclastogenesis assays after TRAP staining,
50 (a). Osteoclastogenesis was quantiﬁed by measuring TRAP5b activity and
counting the number of TRAP+ multinucleated cells/well. The positive effect of
MDA-MB-231 conditioned medium (CM) in stimulating osteoclastogenesis was
lower if breast cancer cells were exposed to AT-406 (1 mM). The effect of breast
cancer cells CMs was independent of RANKL stimulus (2.5 mg/ml) (a and b). n¼3,
npo0.01, nnnpo0.005, using one-way ANOVA with a Newman–Keuls multiple
comparison test.
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targeting it to the proteosome [29,30]. RANK activation induces
release of NIK and activation of the non-canonical NF-κB pathway,
leading to the up-regulation of osteogenic transcription factors like
Nfatc1 and osteoclast differentiation [29,30]. On the other hand,
activation of the canonical NF-κB pathway, via RANKL–RANK–
TRAF6, up-regulates cIAP1 and 2 and inhibits cell death [23,31].
This dual effect of IAPs in osteoclastogenesis and osteoclast
survival led us to assess the effect of AT-406 on osteoclastogenesis.
We found that AT-406 increases osteoclast differentiation in a
dose-dependent manner, but independent of IAPs up-regulation.
However, AT-406 induced a 2.5-fold increase in Nfactc1, at the
early stages of osteoclast differentiation. Upon removal of RANKL
mature osteoclasts enter apoptosis, which was increased by
AT-406. We also demonstrate that breast cancer cells exposed to
AT-406 are less osteogenic. Although the conditioned medium
from breast cancer cells treated with AT-406 still increased
osteoclastogenesis (3-fold), it was signiﬁcantly lower than the
effect of the conditioned medium from untreated cells. This effectis most probably due to breast cancer derived factors, and not to
AT-406, since mouse monocytes were cultured with RANKL,
impairing AT-406-induced apoptosis.
Pharmacokinetics analysis of AT-406 on SCID mice bearing
MDA-MB-231 tumors has shown that AT-406 achieves a maximum
concentration in plasma between 1.5 μM and 9.9 μM, and a
maximum concentration in tumor tissue between 0.5 μM and
18.2 μM, depending on the dose and administration route (intra-
venous versus oral gavage) [11]. Therefore, the described effects of
AT-406 concentrations ranging from 100 nM to 1 μM may be
further increased in vivo.
Results from this work indicate that despite the anti-tumoral
effect of AT-406, its use in the context of bone metastatic disease
needs to be carefully monitored for the induction of increased
bone resorption. In this case, the use of AT-406 with an anti-
resorptive agent could be beneﬁcial. The combination of AT-406
with bisphosphonates for example could compensate for the
increase in bone resorption. We also hypothesize that the combi-
nation of AT-406 with anti-RANKL directed therapies could have a
beneﬁcial effect, especially in RANK-positive tumors. In these
cases, the lack of available RANKL could prevent the induction of
metastatic phenotype of cancer cells triggered by RANK activation,
decrease the de novo osteoclastogenesis, and increase the apopto-
sis of mature osteoclasts via AT-406.Conﬂict of interest statement
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